Frontiers in Clinical Drug Research – Hematology is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of hematological disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of anemias, coagulopathies, vascular diseases and hematological malignancies.
Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology, and vascular pharmacology.
The fifth volume of this series features:
Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology, and vascular pharmacology.
The fifth volume of this series features:
- Recent advances in the diagnosis and management of pulmonary embolism
- An evidence-based approach to treatment with iron chelators in transfusion-dependent thalassemia patients: present trends and future scenarios
- Current and future treatments of iron overload in thalassemia patients
- Preeclampsia: biological and clinical aspects
- Hematological modulations by fixed-dose combination (FDC) of tramadol hydrochloride/paracetamol (THP)
- Possible use of eculizumab in critically ill patients infected with Covid-19 role of complement c5, neutrophils, and nets in the induction DIC, sepsis, and MOF hematological markers
- Emerging diagnostic and therapeutic targets in preeclampsia
Table of Contents
Chapter 1 Recent Advances In The Diagnosis And Management Of Pulmonary Embolism- Oogenesis and Pathophysiology Factors
- Non-thrombotic Pulmonary Embolism
- Clinical Presentation sis Clinical Probability Scores mer Testing
- Computed Tomography Pulmonary Angiography (CTPA) relation-Perfusion Scan (V/Q Scan)
- Pulmonary Angiography Lower Extremity Venous Ultrasonography r Diagnostic Techniques
- Echocardiography Standard Laboratory Examination
- Management ial Management trial Anticoagulation
- Risk Stratification systemic
- Thrombolysis
- Catheter-Directed Thrombolysis Embolectomy or Vena Cava (IVC)
- Filters Long-Term Anticoagulation of Pulmonary Embolism
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgments
- References
Chapter 2 An Evidence-Based Approach To Treatment With Iron Chelators In Transfusion
- Dependent Thalassemia Patients: Present Trends And Future Scenario
- Introduction and Global Distribution of the Thalassemia
- Clinical Classification Of Thalassemia Syndromes [1 - 3, 12, 13]
- Laboratory Determination Of Thalassemia Pathophysiology In Thalassemia Patients
- Βeta-Thalassemia Alpha Thalassemia Blood Transfusions
- Transfusion Therapy in TDT [1, 25 - 29]
- Diverse Reactions vantages of Transfusion Therapy in NTDT
- Mechanism of Iron Overload in TDT Patients
- Mechanism of Iron Overload in NTDT Patients
- Hemochromatosis Complications in TDT and NTDT Patients
- Diagnosis and Quantification of Hemochromatosis in Thalassemia Patients
- Magnetic Resonance Imaging
- Serum Ferritin Assessment
- Chelation Therapy
- Goals of Iron Chelation Therapy and Chelatable Iron
- Chemical and Pharmacological Properties of Iron Chelators
- Management Of Iron Overload With Individual Iron Chelators: A Practical Prescribing Based Approach Roxamine Monotherapy Unions
- Deferiprone Monotherapy He Following Precautions Need To Be Taken While On Deferiprone
- Ferasirox Monotherapy Xjade and Jadenu Combination Therapies Of Iron Chelators In TDT Patients
- Deferoxamine and Deferiprone Combination Therapy
- Xamine+ Deferasirox and Deferiprone and Deferasirox Combination Therapy
- Treatment Of Iron Overload After Stem Cell Transplantation
- Guidelines For Iron Chelation Therapy and Recommendations From Thalassemia International Federation Guidelines 2014
- Alian Guidelines
- Guidelines 3 Patient Compliance To It
- Ical Studies On Twice-Daily Dosing of Deferasirox E
- Directions in Treating Iron Overload in Thalassemia Patients
- In The Available Chelators Oral Iron Chelator (Sp-420)
- E Therapy and Gene Editing
- New Promising Treatments Aiming Hemochromatosis on Metabolism Modulating Agents
- Conclusion
- Abbreviations
- Consent For Publication
- Conflict Of Interest
- Acknowledgments
- References
Chapter 3 Current And Future Treatments Of Iron Overload In Thalassemia Patients
- The Pathophysiological Basis of Iron Overload on Regulation and Homeostasis
- Intestinal Iron Absorption Ron Recycling
- Storage in Transport In Blood Circulation Loss
- Iron Regulation And Signaling Pathway
- Transfusional Iron Overload In Thalassemia Patients
- Complications in Thalassemia Patients with Iron Overload Ac Complications
- Liver Complications
- Crime Complications
- Growth Retardation
- Hypogonadism Hypothyroidism
- Hypoparathyroidism Renal Insufficiency Betes Mellitus
- Pulmonary Hypertension
- Bone Complications And Osteoporosis
- Infectious Complications
- Renal Complications
- ENT Treatment Of Iron Overload
- Iron Chelation Therapy
- Indication of Iron Chelation Therapy
- Monitoring Iron Overload Single-Agent Therapy Examines Deferiprone Deferasirox
- Combination of Chelating Agents Imitations of Current Iron Chelators
- Novel Therapies and Ongoing Clinical Trials In Thalassemia
- TGF-β Activin Receptor Traps
- Sotatercept
- Luspatercept PEGylated
- Erythropoietin
- JAK 2 Inhibitor
- Hepcidin Agonists and Derivatives Reporting Inhibitor
Author
- Atta-ur-Rahman
